WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a fireside chat at 10:00 a.m. E.T. on Tuesday, November 12, 2024 at Guggenheim's Inaugural Healthcare Innovation Conference in Boston, MA.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-38433 Q32 Bio Inc. (Exact name of registrant as specified in its charter) Delaware 47-3468 ...

财务数据关键指标变化 - 2024年第二季度研发费用为1341.1万美元，较2023年同期的801.7万美元增加539.4万美元[8][19] - 2024年第二季度一般及行政费用为450.8万美元，较2023年同期的246.3万美元增加204.5万美元[9][19] - 2024年第二季度净亏损为1700万美元，即每股基本和摊薄净亏损1.42美元，2023年同期净亏损为580万美元，即每股基本和摊薄净亏损16.69美元[10][19] - 截至2024年6月30日，现金、现金等价物和短期投资为107,647千美元，2023年12月31日为25,617千美元，增长约319.81%[20] - 截至2024年6月30日，权益法投资为3,275千美元，2023年12月31日为0千美元[20] - 截至2024年6月30日，使用权资产（经营租赁）为6,016千美元，2023年12月31日为6,301千美元，下降约4.52%[20] - 截至2024年6月30日，受限现金和受限现金等价物为647千美元，2023年12月31日为5,647千美元，下降约88.54%[20] - 截至2024年6月30日，总资产为124,207千美元，2023年12月31日为47,057千美元，增长约163.95%[20] - 截至2024年6月30日，应付账款、应计费用和其他流动负债为13,504千美元，2023年12月31日为13,231千美元，增长约2.06%[20] - 截至2024年6月30日，CVR负债为3,690千美元，2023年12月31日为0千美元[20] - 截至2024年6月30日，风险债务为12,554千美元，2023年12月31日为5,459千美元，增长约129.97%[20] - 截至2024年6月30日，可转换票据为0千美元，2023年12月31日为38,595千美元，下降100%[20] - 截至2024年6月30日，股东权益（赤字）为33,511千美元，2023年12月31日为 - 182,921千美元，增长约118.32%[20] 各条业务线表现 - bempikibart治疗特应性皮炎（AD）的2期临床试验完成入组，试验规模增至121名患者，预计2024年第四季度公布顶线结果[1][2] - bempikibart治疗斑秃（AA）的2期临床试验进展顺利，预计2024年第四季度公布顶线结果[1][4] - ADX - 097治疗补体介导的肾脏疾病的2期篮子试验正在招募患者，预计2024年底公布初步开放标签数据，2025年下半年公布顶线结果[1][5] - 公司计划于2025年上半年启动ADX - 097在抗中性粒细胞胞浆抗体相关性血管炎（AAV）的第二项2期临床试验，预计2025年下半年公布顶线结果[2][5] - SIGNAL - AD是一项两部分的2期临床试验，评估bempikibart治疗成人持续性、中重度AD，A部分已完成但数据仍处于盲态，B部分正在进行[2][3] - bempikibart治疗AA的2期临床试验中，患者按3:1随机分配至bempikibart 200mg每两周一次皮下注射固定剂量组和安慰剂组，治疗24周[4] 其他没有覆盖的重要内容 - 截至2024年6月30日，公司现金、现金等价物和短期投资为1.076亿美元，预计可支撑到2026年年中[1][7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-38433 Q32 Bio Inc. (Exact name of registrant as specified in its charter) Delaware 47-346 ...

Exhibit 99.1 Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update -- Completed enrollment in bempikibart alopecia areata (AA) Phase 2 clinical trial, with topline results expected in Q4'24; enrollment in bempikibart atopic dermatitis (AD) Phase 2 clinical trial remains ontrack, with topline results expected in Q4'24 -- -- ADX-097 continues to advance, with anticipated Phase 2 clinical trial initiations on-track: renal basket in 1H'24 and ANCA-associated vasculitis (AAV) in 1H'2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38433 Homology Medicines, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-3468154 (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-38433 Homology Medicines, Inc. (Exact Name of Registrant as Specified in its Charte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-38433 Homology Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-38433 Homology Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38433 Homology Medicines, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-3468154 (State or other jurisdicti ...